Compare · NVO vs SYBX
NVO vs SYBX
Side-by-side comparison of Novo Nordisk A/S (NVO) and Synlogic Inc. (SYBX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both NVO and SYBX operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO carries a market cap of $172.11B.
- NVO has been more active in the news (9 items in the past 4 weeks vs 5 for SYBX).
- NVO has more recent analyst coverage (25 ratings vs 6 for SYBX).
- Company
- Novo Nordisk A/S
- Synlogic Inc.
- Price
- -
- -
- Market cap
- $172.11B
- -
- 1M return
- -0.41%
- -
- 1Y return
- -18.26%
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2015
- News (4w)
- 9
- 5
- Recent ratings
- 25
- 6
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Synlogic Inc.
Synlogic, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of synthetic biotic medicines to treat metabolic, inflammatory, and cancer diseases in the United States. Its therapeutic programs include SYNB1618, an oral therapy that is in Phase II clinical trial to treat phenylketonuria (PKU), as well as pre-clinical stage product SYNB1934 for the treatment of PKU; and SYNB8802 that is in Phase I clinical trial for the treatment of Enteric Hyperoxaluria. The company is also developing SYNB1891, an intratumorally administered synthetic biotic medicine that is in Phase I clinical trial to treat solid tumors and lymphoma. It has a collaboration agreement with Ginkgo Bioworks for the development of synthetic biotic medicines. Synlogic, Inc. is headquartered in Cambridge, Massachusetts.
Latest NVO
- Novo launches the new Novocare®: Free support program connects people with Wegovy® in addition to home delivery, everyday support, wellness partners and rewards
- SEC Form 6-K filed by Novo Nordisk A/S
- Novo and DJ Khaled team up to take fans behind the scenes of the iconic musician's real-life "Walk, Golf, and Wegovy®" diet and weight-loss routine
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Billions in New Plants, Trillions in Potential Obesity-Drug Revenue Over Two Decades
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
Latest SYBX
- SEC Form 10-Q filed by Synlogic Inc.
- SEC Form 425 filed by Synlogic Inc.
- Caldera Therapeutics Reports New CLD-423 Phase 1a Data and Expands Immunology and Inflammation Pipeline With Anti IL-17 X TL1A Bispecific Antibody Program
- SEC Form 425 filed by Synlogic Inc.
- Caldera Therapeutics Appoints Michelle Doig as Chief Financial Officer and Lee Giguere as Chief Legal Officer
- SEC Form 10-Q filed by Synlogic Inc.
- SEC Form 425 filed by Synlogic Inc.
- Synlogic Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Regulation FD Disclosure
- Synlogic and Caldera Therapeutics Announce Merger Agreement and Concurrent Private Placement
- SEC Form 25-NSE filed by Synlogic Inc.